Phase 3 IGIV, 10% in Alzheimer´s Disease

Inclusion Criteria:

- Males or females of age 50 to 89 years inclusive at the time of screening

- Written informed consent obtained from either the subject or the subject's legally
authorized representative prior to any study-related procedures

- Written informed consent obtained from an able and competent caregiver who is willing
to comply with the requirements of the protocol pertaining to him/her, including
facilitating the subject's participation in the study

- Diagnosis of Probable Alzheimer´s Disease (AD) according to NINCDS-ADRDA* 1984
criteria (* National Institute of Neurological and Communicative Disorders and Stroke
- Alzheimer's Disease and Related Disorders Association)

- Dementia of mild to moderate severity (Mini-Mental State Examination [MMSE] 16-26
inclusive at the time of screening)

- Neuroimaging (computed tomography [CT] or MRI) performed after symptom onset
consistent with AD diagnosis

- Willingness to comply with the requirements of the protocol and ability to comply with
testing and infusion regimen, including adequate corrected visual acuity and hearing
ability

- For at least 12 weeks prior to screening, on stable doses of AD medication(s) approved
by local regulatory authorities. Subjects must not be on two acetylcholinesterase
inhibitors concurrently.

- Venous access for repeated infusion and phlebotomy

- If receiving psychoactive medications (eg, antidepressants other than monoamine
oxidase inhibitors [MAOIs] and most tricyclics, antipsychotics, anxiolytics,
anticonvulsants, mood stabilizers, etc.), must be on stable doses for at least 6 weeks
prior to screening

- For women of childbearing potential, the subject must have a negative pregnancy test
at screening and must agree to employ adequate contraceptive measures (eg, birth
control pills/patches, intrauterine device, or diaphragm or condom [for male partner]
with spermicidal jelly or foam) throughout the course of the study

- For subjects with a coronary artery stent, the subject must receive documented medical
clearance from an interventional cardiologist stating that the subject is not at
increased risk for stent occlusion with immunoglobulin treatment

- For subjects with an endovascular stent, the subject must receive documented medical
clearance from a vascular surgeon stating that the subject is not at increased risk
for thromboembolic events with immunoglobulin treatment

Main Exclusion Criteria:

- Possible AD by NINCDS-ADRDA criteria or non-Alzheimer dementia (eg, vascular dementia,
dementia with Lewy bodies, frontotemporal dementia, or dementia arising from other
diseases or conditions such as Parkinson's disease, vitamin B12 deficiency, thyroid
abnormalities)

- Current residence in a skilled nursing facility

- Contraindication to undergoing MRI (eg, pacemaker [with the exception of an
MRI-compatible pacemaker], severe claustrophobia, ferromagnetic implants such as a
metal plate)

- Clinically significant congestive heart failure (eg, New York Heart Association [NYHA]
Class III/IV symptoms or untreated Class II)

- Current atrial fibrillation of unstable angina (angina at rest) or history of
myocardial infarction within the 12 months prior to screening

- Uncontrolled hypertension defined as systolic blood pressure > 160 mm Hg and/or
diastolic > 100 mm Hg confirmed upon repeated measures

- History of thrombosis and/or thromboembolic disease (central or peripheral) within the
12 months prior to screening

- Known history of procoagulant abnormalities (eg, factor V Leiden, antiphospholipid
syndrome, protein S/protein C deficiency, AT III deficiency)

- History of intracerebral hemorrhage within the 5 years prior to screening

- Evidence on MRI of: greater than 4 microhemorrhages (regardless of their anatomical
location or diagnostic characterization as "possible" or "definite"), a single area of
superficial siderosis, vasogenic edema, a macrohemorrhage, major stroke, prominent
white matter disease with a rating score of 3 on the age-related white matter changes
(ARWMC) scale from the European Task Force on ARWMC, or multiple lacunae (defined as
more than 2 lacunae that are greater than 0.5 mm in size)

- Head trauma with loss of consciousness, contusion, or open head injury within the 12
months prior to screening

- Uncontrolled seizure disorder as defined by two or more breakthrough seizures per year
despite adequate antiepileptic drug (AED) treatment

- Modified Hachinski score > 4 at time of screening

- Subjects with active malignancy or history of malignancy within 5 years prior to
screening with the exception of the following: adequately treated basal cell or
squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable
prostate cancer not requiring treatment

- Active autoimmune or neuro-immunologic disorder

- Uncontrolled major depression, psychosis, or other major psychiatric disorder(s)

- Poorly controlled diabetes, defined as glycosylated (or glycated) hemoglobin (HbA1c) ≥
6.5% at screening

- Creatinine clearance < 50% of normal adjusted for age and gender, as calculated
according to the Cockcroft-Gault formula, at the time of screening

- Known history of untreated vitamin B12 deficiency within 6 months prior to screening,
or clinically significant abnormally low vitamin B12 at the time of screening

- Abnormal clinical chemistry panel or hematology panel meeting any one of the following
criteria:

- Serum alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN)

- Clinically significant anemia that precludes repeated blood sampling or hemoglobin
(Hgb) < 10.0 g/dL

- Absolute neutrophil count (ANC) < 1000 cells/µL

- Known coagulopathy or platelet counts < 100,000 cells/µL

- Total serum protein > 9 g/dL

- Known history of or positive serology at screening for one or more of the following:
hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human
immunodeficiency virus (HIV) type 1/2 antibody

- Immunoglobulin A (IgA) deficiency (< 8 mg/dL)

- Known history of hypersensitivity following infusions of human blood or blood
components (e.g. human immunoglobulins or human albumin)

- Currently receiving or has received: anti-CD20 therapy within 12 months prior to
screening, or other immunomodulatory therapies (e.g. anti-TNF, anti-IL-1, interferon)
within 12 weeks prior to screening. The following exceptions are allowed: non-systemic
corticosteroids (eg, topical, opthalmic or inhaled glucocorticoids) and low-dose
systemic corticosteroids (prednisone < 10 mg/day or its equivalent)

- Currently receiving or has received intravenous or subcutaneous immunoglobulin
treatment within the 2 years prior to screening, or has received immunoglobulin in
Baxter Protocol 160701

- Currently receiving or has received at any time active immunization aimed at
modulating AD progression

- Currently receiving or has received within 12 months prior to screening any
investigational device, drug or biologic (eg passive immunotherapies with monoclonal
or polyclonal antibodies) aimed at modulating AD progression

- Subject has been exposed to an investigational product (IP) or investigational device
within 12 weeks prior to screening or is scheduled to participate in another clinical
study involving an IP or investigational device during the course of this study

- Subject is a family member or employee of the investigator

- The subject is nursing or intends to begin nursing during the course of the study

- Any disorder or disease, or clinically significant abnormality on laboratory or other
clinical test(s) (eg, blood tests, urine tests, electrocardiogram, chest x-ray), that
in medical judgment may impede the subject's participation in the study, pose
increased risk to the subject, or confound the results of the study

- Currently receiving anti-coagulant agent and/or anti-platelet agent other than
acetylsalicylic acid (a.k.a. aspirin)